On 16 December 2014, orphan designation (EU/3/14/1385) was granted by the European Commission to Immodulon Therapeutics Ltd, United Kingdom, for heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.
The sponsorship was transferred to Immodulon Therapeutics B.V., Netherlands, in August 2019.
The sponsorship was transferred to Regintel Limited, Ireland in March 2022.
Heat-killed Mycobacterium obuense (whole cell)
Treatment of pancreatic cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: